Curevo Vaccine Announces $26 Million Series A1 Financing To Support Clinical Development Of Next-Generation Subunit Vaccines
Curevo Vaccine Announces $26 Million Series A1 Financing To Support Clinical Development Of Next-Generation Subunit Vaccines
11/16/22, 3:04 PM
Location
bothellMoney raised
$26 million
Industry
sports
platforms
mobile
Round Type
series a
Investors
Adjuvant Capital, Ra Capital Management, Janus Henderson Investors
Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced the closing of a $26 million Series A1 financing round.
Company Info
Location
bothell, washington, united states
Additional Info
Curevo is a privately held, clinical-stage biotechnology company based in Seattle and dedicated to reducing the burden of infectious disease by developing safe and highly effective vaccines via its sub-unit vaccine technology platform. Its lead product is CRV-101, a sub-unit vaccine to prevent the reactivation of the varicella zoster virus (shingles) in older adults. Shingles is a serious medical condition involving a blistering skin rash where 1 in 10 people also develop serious, lasting nerve pain. The nearly $4 billion shingles global vaccine market is characterized by product shortages and a high burden of vaccine-related side effects. Curevo is also developing a non-live, subunit chickenpox vaccine. For more information visit https://curevovaccine.com/.
Shingrix® is a registered trademark of GlaxoSmithKline, PLC.